Your trusted source for investing success

Tag: pipeline

Cruz Cobalt receives TSX-V OK for name change

Cruz Cobalt receives TSX-V OK for name change

Cruz Cobalt (TSXV:CUZ) has received TSX Venture Exchange approved for its name change to Cruz Cobalt Corp., as previously announced on Feb. 9, 2017. Effective at the open on Feb. 23, 2017, the common shares of Cruz Cobalt will commence trading on the TSX Venture Exchange, and the common shares

Brixton Metals plans drill test at Chivas

Brixton Metals plans drill test at Chivas

Brixton Metals Corp. has released project updates for its gold-silver properties located in both Ontario and British Columbia, Canada.

The company has filed with the mineral title division of the Ministry of Energy, Mines and Petroleum Resource the 2016 assessment report on the Thorn project located in Northwest British Columbia.

Revive Therapeutics Announces Term Sheet with InMed Pharmaceuticals for the Discovery and Development of Cannabinoid-Based Therapy Targeting Kidney Diseases

Revive Therapeutics (TSX VENTURE:RVV)(OTCQB:RVVTF), today announced the Company has entered into a term sheet agreement with InMed Pharmaceuticals Inc. (“InMed”) for the discovery and development of cannabinoid-based therapies targeting kidney diseases.

“I am very excited to be partnering with InMed and utilizing their proprietary Bioinformatics Database Assessment Tool, an in-silico technology

NeoGenomics Reports 122% Revenue Growth to $60.5 Million and 11% Reduction in Average Cost per Test in the Fourth Quarter of 2016

NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today reported its results for the fourth quarter and full year 2016.

Fourth Quarter 2016 Highlights:

140% increase in clinical genetic testing volume(1)
122% increase in consolidated revenue to $60.5 million
11% reduction in average cost per clinical genetic

VBI Vaccines Receives Positive Response from Health Canada’s Initial Evaluation of the Proposed Sci-B-Vac Phase III Clinical Program

VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) (“VBI”) announced today that the Biologics and Genetic Therapies Directorate (BGTD) of Health Canada expressed its general support and acceptance of the company’s development path for its Sci-B-Vac™ vaccine, a prophylactic vaccine against hepatitis B, in a pre-Clinical Trial Application (“CTA”) meeting. A complete CTA must

Millennial, Southern Lithium complete Cruz survey

Millennial, Southern Lithium complete Cruz survey

Millennial Lithium (TSXV:ML;OTCQB:MLNLF) has released positive results of a recently completed ground geophysics program at its Cruz property, located in the Pocitos salar basin in Salta province, Argentina. The Cruz Property is being explored in partnership with Southern Lithium Corp. which has an option to acquire up to 80% of

Marrone Bio Innovations Hosts Grower Nematicide Training

Marrone Bio Innovations, Inc. (MBI), (NASDAQ:MBII), a leading manufacturer and marketer of bio-based pest management and plant health products for the agriculture, turf and ornamental, and water treatment markets, hosted a training featuring eight Florida and Georgia experts reviewing the most current data on nematode management. Enrolled in this CEU

Immuron Completes Phase II NASH Clinical Trial Recruitment

Immuron Limited (ASX:IMC), an Australian biopharmaceutical company focused on oral immunotherapy utilizing polyclonal antibody products to target immune-mediated diseases, today announced that the Company’s IMM-124E Phase II clinical trial for the treatment of NASH (Non-Alcoholic Steatohepatitis) has successfully reached its full recruitment milestone of 120 randomized patients.
The Phase II, multicenter,

Energy Fuels receives EPA aquifer exemption for Nichols

Energy Fuels receives EPA aquifer exemption for Nichols

Energy Fuels Inc. (TSX:EFR,NYSEMKT:UUUU) has provided an update. The U.S. Environmental Protection Agency (EPA), in a letter dated Feb. 10, 2017, has issued an aquifer exemption for the Jane Dough well field in the Nichols Ranch ISR project pursuant to the requirements of 40 CFR paragraph 146.4. In the letter,

Abeona Therapeutics Provides Update from ABO-102 Phase 1/2 MPS IIIA Clinical Trial at the 13th Annual WORLDSymposium™ 2017

Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing therapies for life-threatening rare genetic diseases, announced updated data from the ongoing gene therapy clinical trial for Sanfilippo syndrome Type A (MPS IIIA), at the 13th Annual WORLDSymposium™ 2017 lysosomal storage disorders conference in San Diego, CA. The

Immune Pharmaceuticals Announces the launch of REMAIN ™ , an international Overall Survival study with Ceplene® and low dose Proleukin® in REmission MAINtenance in Acute Myeloid Leukemia

Immune Pharmaceuticals Inc. (Nasdaq: IMNP), will announce on Monday, February 20th, 2017 at the Acute Leukemia XVI symposium in Munich, Germany that it will be launching REMAIN™, an international Overall Survival clinical study with the combination of Ceplene®, the Company’s flagship product for Acute Myeloid Leukemia (AML) remission maintenance and

Biotech Stock Up 43% on Cannabis Expansion

Biotech Stock Up 43% on Cannabis Expansion

Revive Therapeutics’ stocks jumped by 43 percent on Thursday after the company announced that it is expanding its product pipeline by developing cannabinoid-based therapeutics specifically for liver diseases.

Revive Therapeutics Announces Expansion into Cannabinoid-Based Therapies Targeting Liver Diseases

Revive Therapeutics (TSX VENTURE:RVV) (OTCQB:RVVTF), a company focused on the research, development and commercialization of novel treatments for serious and unmet medical needs, today announced the Company is expanding its product pipeline through the development of cannabinoid-based therapeutics targeting liver diseases.

“Through our dedicated bioinformatics platform specifically designed to identify repurposed

Clearside Biomedical Announces First Patient Randomized in Phase 3 Clinical Trial of Zuprata™ Used Together With Eylea in Subjects With Retinal Vein Occlusion

Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced the enrollment of the first patient in a Phase 3 clinical trial (“SAPPHIRE”) of Zuprata™, its proprietary suspension formulation of the corticosteroid triamcinolone acetonide, used together with EYLEA® (aflibercept) for the treatment

Enter Your Log In Credentials
×

Privacy & Legal Policy

This website is part of the Investing News Network published by Dig Media Inc.

Overview

INN's mission is to be the world's number one source of independent, unbiased news and education helping investors realized their financial goals. We also strive to be internationally respected for our integrity, our people and our commitment to excellence. Therefore, we are very concerned with the privacy rights of our audience and are committed to protecting the information collected about you.We have taken extensive measures to protect the confidentiality of your personal information and to protect your data from misuse and unauthorized access or disclosure. Unfortunately, no data transmission over the Internet can be guaranteed to be 100% secure. As a result, Dig Media cannot ensure or warrant the security of the information you transmit to us and you do so at your own risk.

Contact Information

Our postal address is

L200 - 560 Beatty Street,

Vancouver, BC V6B 2L3

We can be reached via e-mail at info@digmediasolutions.com or telephone at +1-604-688-8231

Information Collected

For each visitor to our website, our web server automatically recognizes no information regarding the domain or e-mail address.

We collect information volunteered by the visitor, such as survey information and/or site registrations, name and address, telephone number.

The information we collect is used to notify visitors about updates to our website, shared with other reputable organizations to help them contact visitors for marketing purposes.

With respect to cookies: When you visit our websites, we send one or more cookies, a small file containing a string of characters, to your computer that uniquely identifies your browser during your visit. We use these cookies to maintain your connection as you move from page to page, and to ensure anything you submit, such as a comment or a form, is not rejected. You can reset your browser to refuse all cookies or to indicate when a cookie is being sent. However, some website features or services may not function properly without cookies.

If you do not want to receive e-mail from us in the future, please let us know by sending us e-mail at the above address.

Persons who supply us with their telephone numbers on-line may receive telephone contact from us with information regarding new products and services or upcoming events. If you do not wish to receive such telephone calls, please let us know by sending us e-mail at the above address.

Ad Server

With respect to Ad Servers:

Other third-party companies which place advertising on our site may collect information about you when you view or click on their advertising through the use of their cookies or other tracking technologies, which may include delivering targeted advertisements and marketing messages based upon the third party websites that you visit, or other purposes. We cannot control this collection of information and are not responsible for the privacy policies and data collection, use and disclosure practices of these third party advertisers. You should contact these third party advertisers directly if you have any questions about their use of the information that they collect from you. Google-DoubleClick DFP is our third party ad server. If you would like to know more about their information gathering practices and opt-out procedures, please see Google ad policies.

Also, if you would like more information about this practice and to know your choices about not having this information used by these companies, please see NAI Opt-out Options.

Information Use

We only share personal information with other companies or individuals outside of the cases outlined above in the following limited circumstances:

We may share with third parties certain pieces of aggregated, non-personal information, such as the number of users who searched for a particular term, for example, or how many users clicked on a particular advertisement. Such information does not identify you individually.

Remarketing

We may remarket your information. Remarketing is a way for us to connect with users, based upon your past interactions with INN websites. Third-party marketing vendors may be hired by INN to perform remarketing services. As a result, third-party vendors, including Google, may show INN ads on sites on the internet. Third-party vendors, including Google, use cookies to serve ads based on a user's prior visits to INN websites.

To opt out of customized Google Display Network ads click here. To find out more about how Google uses any data it collects please visit http://www.google.com/privacy_ads.html.
Any information collected is used only for remarketing purposes and will not be used by them for any other purpose.

Future Use

From time to time, we may use visitor information for new, unanticipated uses not previously disclosed in our privacy notice. If our information practices change at some time in the future we will post the policy changes to our website to notify you of these changes and provide you with the ability to opt out of these new uses. If you are concerned about how your information is used, you should check back at our website periodically.

Accessing Your Data

Please contact us at the address above for any additional questions about the management or use of personal data.

Upon request we provide site visitors with access to communications that the visitor has directed to our site (e.g., e-mails, customer inquiries), contact information (e.g., name, address, phone number) that we maintain about them.

Visitors can access this information by e-mailing us at the above address.

Upon request we offer visitors the ability to have inaccuracies corrected in contact information.

Visitors can have this information corrected by sending us e-mail at the above address.

Security

With respect to security: We have appropriate security measures in place in our physical facilities to protect against the loss, misuse or alteration of information that we have collected from you at our site.

Your Acceptance of These Terms

By using this site, or by submitting personal information to us, you signify your agreement to Dig Media's Privacy Policy and Terms of Use. From time to time we may change or update our piracy policies. It is your responsibility to check back regularly to inform yourself of such changes. Your continued use of this or any Dig Media website following the posting of changes to these terms will be deemed as your acceptance of those changes.

The foregoing policies are in effect as of August 1, 2012. Dig media reserves the right to change this policy statement at any time by posting the revised policy to this website. This statement and the policies outlined herein are not intended to and do not create any contractual or other legal rights in or on behalf of any party.

If you feel that this site is not following its stated information policy, you may contact us at the above addresses or phone number.

×
Investing News Network